About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT01962155

Prospective Stuy in Evaluating Hepatic Fibrosis Related to Hepatitis B Virus Using Non-invasive Parameters

The aim of our prospective study is to construct and validate a non-invasive model consisting biochemical markers, FibroScan, and radiological parameters for evaluating liver fibrosis caused by hepati...

Lead sponsor: Peking University First Hospital•30 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Peking University First Hospital

Up to Oct, 2015,total of 1800 patients with chronic HBV infection were enrolled. Paired blood and liver biopsy samples were collected. Blood samples stored at -80 degree Celsius. Liver biopsy samples were judged by three pathology experts.

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. HBsAg positive for at least 6 months
•2. agree to have liver biopsy
•3. Male or female aged 18 to 65 years old

Exclusion Criteria

•1. Patients with alcoholic liver disease, autoimmune liver disease, heretic liver disease, drug induced liver disease,nonalcoholic liver disease or other chronic liver disease
•2. platelet count \< 80000/L
•3. prothrombin activity ≤ 60%
•4. patients with any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject

Related studies

RECRUITINGPhase 3

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

NCT06632444 · Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis

RECRUITINGPhase 2

VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B

NCT06092333 · Chronic Hepatitis B

Real World Assessment of People Living With Chronic Hepatitis B in Australia

NCT04914611 · Hepatitis B

Correlation Of EUS-SWQ And Liver Fibrosis Pathology In Chronic Liver Disease

NCT07588854 · Chronic Liver Disease (CLD), Liver Fibrosis

RECRUITINGPhase 1

The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.

NCT07069725 · Liver Fibrosis, Hepatic Cirrhosis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 9, 2016Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment1,841

Start dateAug 2013

Last updatedSep 9, 2016

Condition

Hepatitis B Liver Fibrosis

Locations shown

The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui

302 Military Hospital of China

Beijing, Beijing Municipality

Beijing Ditan Hospital

Beijing, Beijing Municipality

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 9, 2016Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions